SRSF7 Antibody

What is SRSF7 and why is it significant in cellular function?

SRSF7 (also known as 9G8) is a member of the serine/arginine-rich (SR) family of mRNA processing factors that plays diverse roles in gene expression regulation. The canonical human protein has 238 amino acids with a mass of 27.4 kDa and localizes to both the nucleus and cytoplasm . SRSF7 functions in:

• Pre-mRNA splicing and alternative splicing regulation

• mRNA nuclear export (particularly for histone H2A)

• Transcriptional activation (notably of interferon regulatory factor 7)

• RNA polymerase II elongation regulation

• Alternative polyadenylation

Recent research has revealed that SRSF7 has unorthodox roles beyond its canonical splicing function, particularly in immune response, cancer development, and cellular senescence .

What experimental techniques commonly employ SRSF7 antibodies?

SRSF7 antibodies are utilized across various molecular and cellular techniques:

Research shows SRSF7 antibodies are particularly valuable for comparing expression between normal and diseased tissues, with notable applications in cancer and immunity studies .

How should researchers select appropriate SRSF7 antibodies for their experiments?

Selection criteria should include:

• Isoform specificity: SRSF7 has 4 isoforms due to alternative splicing . Review the immunogen sequence to determine which isoforms the antibody will detect.

• Species reactivity: Verify cross-reactivity with your experimental organism. Many antibodies are validated for human samples, with some showing reactivity to mouse and rat SRSF7 .

• Application validation: Choose antibodies validated for your specific application through demonstrated use in publications.

• Epitope location: Antibodies targeting different regions may give varying results:

  • N-terminal domain antibodies: Recognize the RNA recognition motif

  • C-terminal domain antibodies: Target the SR-rich domain where phosphorylation occurs

• Validation methods: Prefer antibodies validated through multiple methods, particularly those tested with knockdown/knockout controls .

How can researchers effectively use SRSF7 antibodies to study its role in innate immunity?

SRSF7 has recently been identified as a critical regulator of antiviral responses in macrophages . To investigate this role:

• Transcription factor binding analysis: Use ChIP assays with SRSF7 antibodies to study its association with the Irf7 promoter, where SRSF7 enables STAT1 recruitment and relieves RNA polymerase II pausing .

• Pathogen response studies: Monitor SRSF7 phosphorylation and expression following exposure to pathogens such as:

  • Bacterial LPS (100 ng/ml)

  • Vesicular stomatitis virus (VSV)

  • Salmonella infection

  • Mycobacterium tuberculosis

• Protein-chromatin network analysis: Investigate SRSF7's cooperation with histone methyltransferase KMT5a (SET8) to regulate H4K20me1 deposition at the Irf7 promoter .

• ISG expression profiling: Use SRSF7 knockdown models to identify SRSF7-dependent interferon stimulated genes (ISGs), including Mx1, Ifit3, and the cytosolic DNA sensor Zbp1 .

• Viral restriction assays: Measure viral replication (e.g., VSV) in SRSF7-manipulated cells to assess functional impacts on antiviral immunity .

This approach revealed that SRSF7 knockdown macrophages are permissive to VSV hyper-replication, while SRSF7 overexpression enhances viral restriction .

What methodological approaches enable investigation of SRSF7's role in cancer?

SRSF7 is frequently overexpressed in colon and lung cancers . Key methodological approaches include:

• Expression profiling: Use immunohistochemistry to compare SRSF7 levels between cancerous and normal tissues:

  • Colon adenocarcinoma: Elevated in 21/24 samples

  • Lung carcinoma: Elevated in 22/24 samples

• Functional knockdown studies: Use siRNA to deplete SRSF7 in cancer cell lines (like HCT116 and A549), then assess:

  • Cell proliferation (using MTS assays)

  • Apoptosis (via flow cytometry and spectrofluorometer analyses)

  • Cell cycle progression

• Alternative splicing analysis: Investigate SRSF7's regulation of cancer-relevant splicing events, particularly of the apoptosis regulator Fas .

• Establishing stable cell lines: Create cancer cell lines with stable SRSF7 knockdown or overexpression for long-term functional studies .

• In vivo tumor models: Evaluate tumor growth in nude mice with altered SRSF7 expression levels.

Research has demonstrated that SRSF7 knockdown inhibits proliferation and enhances apoptosis in colon and lung cancer cells, suggesting its potential as a therapeutic target .

How should researchers design experiments to study SRSF7's role in cellular senescence?

SRSF7 appears to protect cells from senescence, with its downregulation promoting senescence phenotypes . Experimental design should include:

• Time-course expression analysis: Monitor SRSF7 mRNA and protein levels during:

  • Replicative senescence (RS) progression

  • Oxidative stress-induced senescence (OSIS)

  Research shows SRSF7 downregulation precedes acquisition of senescence-associated β-galactosidase activity .

• Knockdown studies: Use siRNA-mediated SRSF7 depletion to assess:

  • SA-β-gal activity

  • Senescence marker expression (p16, p21, p27, γH2ax)

  • Cell growth inhibition

• Alternative splicing analysis: Examine how SRSF7 regulates alternative splicing of key senescence mediators:

  • MDM2 splice variants (particularly MDM2-C)

  • p53β, an alternatively spliced form of p53

• p53 pathway investigation: Although SRSF7 knockdown doesn't affect TP53 mRNA levels, it increases p53 protein stability and activity. Examine:

  • p53 protein levels

  • p21 expression

  • MDM2 variant formation

• Rescue experiments: Test whether SRSF7 overexpression can prevent or reverse senescence in:

  • Cells with oncogene-induced senescence (e.g., Neuro2a-RasV12 cells)

  • Cells exposed to DNA damage

This approach revealed that SRSF7 downregulation induces senescence through p53-mediated mechanisms involving alternative splicing of MDM2 .

What are the optimal conditions for SRSF7 antibody use in Western blotting?

For phosphorylated SRSF7 detection, phosphatase inhibitors must be included in lysis buffers, and phospho-specific antibodies or phospho-protein enrichment may be necessary .

What strategies help address discrepancies in SRSF7 detection between different antibodies?

When facing inconsistent results with different SRSF7 antibodies, implement these strategies:

• Epitope mapping comparison: Different antibodies recognize distinct epitopes that may be differentially accessible based on:

  • Protein conformation

  • Post-translational modifications (particularly phosphorylation)

  • Protein-protein interactions

  Compare the immunogen sequences and select antibodies targeting different regions.

• Validation with knockout/knockdown controls: Use siRNA or shRNA to create SRSF7-depleted samples as definitive negative controls .

• Multiple detection methods: Combine Western blotting with other techniques:

  • Immunofluorescence to confirm subcellular localization

  • RT-qPCR to correlate protein with mRNA levels

  • Mass spectrometry for definitive protein identification

• Post-translational modification assessment: SRSF7 undergoes significant phosphorylation that affects antibody recognition:

  • Treat samples with phosphatase before Western blotting

  • Use phospho-specific antibodies when available

  • Run samples on Phos-tag gels to separate differently phosphorylated forms

• Sample preparation optimization: Test different lysis conditions and buffers to ensure complete extraction and maintain protein integrity.

• Blocking optimization: Test alternative blocking agents (milk vs. BSA) as some epitopes may be masked differently.

Research shows SRSF7 detection can vary considerably between antibodies, especially when phosphorylation status changes during cellular responses .

How can researchers effectively validate SRSF7 antibody specificity?

Comprehensive validation should include multiple approaches:

• Genetic depletion controls: Use siRNA/shRNA knockdown or CRISPR/Cas9 knockout models:

  • Several studies successfully employed SRSF7 shRNA in RAW 264.7 macrophages

  • SRSF7 siRNA has been validated in HCT116 and A549 cancer cells

• Peptide competition assay: Pre-incubate the antibody with immunizing peptide:

  • Specific signals should disappear

  • Non-specific signals will remain

  • Titrate peptide concentration to determine optimal blocking

• Multi-antibody validation: Compare results using antibodies from different sources:

  • Polyclonal antibodies: ab137247, ab138022 (Abcam)

  • Monoclonal antibody: #82637 (Cell Signaling Technology)

  • HPA043850 (Sigma-Aldrich)

• Cross-species reactivity testing: If the antibody claims multi-species reactivity:

  • Test in human, mouse, and rat samples

  • Compare band patterns across species

  • Sequence alignment analysis to predict cross-reactivity

• Recombinant protein controls: Include purified recombinant SRSF7 as a positive control.

• Expected expression pattern verification:

  • Nuclear predominance with some cytoplasmic presence

  • Higher expression in proliferating cells

  • Elevated levels in specific cancer types (colon, lung)

• Orthogonal validation: Correlate protein detection with mRNA levels using RT-qPCR.

These validation steps ensure reliable and reproducible results when studying SRSF7 expression and function.

How can researchers investigate SRSF7's non-canonical role in transcriptional regulation?

Recent studies have revealed SRSF7's unexpected function as a transcriptional regulator . To investigate this role:

• Chromatin immunoprecipitation (ChIP): Use SRSF7 antibodies to identify genomic binding sites:

  • Focus on the Irf7 promoter, where SRSF7 has been shown to bind

  • Include appropriate controls (input, IgG, known targets)

  • Use qPCR or sequencing to analyze bound regions

• Transcription factor binding analysis: Examine how SRSF7 affects transcription factor recruitment:

  • ChIP for STAT1 in SRSF7-depleted cells

  • Analyze RNA polymerase II occupancy and phosphorylation

  • Study histone modifications at SRSF7-regulated promoters

• Gene expression profiling: Compare transcriptomes in SRSF7-manipulated cells:

  • RNA-seq following SRSF7 knockdown/overexpression

  • Distinguish transcriptional vs. post-transcriptional effects

  • Analyze SRSF7-dependent genes for common promoter elements

• Histone modification studies: Investigate SRSF7's interaction with chromatin modifiers:

  • The KMT5a (SET8) histone methyltransferase cooperates with SRSF7

  • Focus on H4K20me1 deposition at SRSF7-regulated promoters

  • Assess changes in histone modifications following SRSF7 manipulation

• Protein-protein interaction analysis: Identify SRSF7's nuclear partners:

  • Co-immunoprecipitation with transcription factors and chromatin modifiers

  • Proximity ligation assays for in situ interaction detection

  • Mass spectrometry of nuclear SRSF7 complexes

This approach revealed that SRSF7 promotes Irf7 transcription by recruiting STAT1 and facilitating RNA polymerase II elongation through cooperation with KMT5a .

What approaches enable studying the relationship between SRSF7 and RNA binding specificity?

To investigate how SRSF7 achieves RNA binding specificity:

• CLIP-seq (Cross-linking immunoprecipitation with sequencing): Use SRSF7 antibodies to capture its RNA binding sites:

  • Analyze binding motifs (GAY has been identified for SRSF7)

  • Compare binding patterns near proximal and distal polyadenylation sites

  • Examine binding at alternatively spliced exons

• RNA immunoprecipitation (RIP): Pull down SRSF7-associated RNAs:

  • Analyze bound transcripts by RT-qPCR or sequencing

  • Compare binding under different cellular conditions

  • Correlate binding with splicing/expression changes

• In vitro binding assays: Test direct RNA-protein interactions:

  • Use recombinant SRSF7 with synthetic RNA oligonucleotides

  • Perform RNA EMSA (electrophoretic mobility shift assay)

  • Measure binding affinities for different sequence motifs

• Mutational analysis: Create SRSF7 mutants affecting RNA binding:

  • Target the RNA recognition motif (RRM)

  • Assess how mutations affect RNA binding and functional outcomes

  • Study phosphorylation-dependent RNA binding changes

• Competitive binding studies: Investigate competition between SRSF7 and other RBPs:

  • Focus on coordination with SRSF3, which works with SRSF7 in 3'UTR regulation

  • Examine binding site overlap with other SR proteins

  • Test how binding competition affects alternative splicing outcomes

Research has shown that SRSF7's RNA binding is semi-sequence specific, with the GAY motif particularly enriched at SRSF3-regulated polyadenylation sites .

How can researchers investigate SRSF7's role in alternative polyadenylation?

SRSF7 modulates 3'UTR length through regulation of alternative polyadenylation (APA) . To study this function:

• 3'-end sequencing: Profile polyadenylation site usage:

  • 3'READS (3' region extraction and deep sequencing)

  • PAS-seq (polyadenylation site sequencing)

  • Compare results between SRSF7-depleted and control cells

• Binding site analysis: Examine SRSF7 binding relative to polyadenylation sites:

  • CLIP-seq data shows SRSF7 binding is enriched near polyadenylation sites

  • The GAY motif is particularly enriched at proximal polyadenylation sites (pPASs)

  • SRSF7 can actively bind to pPASs rather than being recruited by other proteins

• Minigene assays: Test how SRSF7 affects polyadenylation site choice:

  • Construct reporters with competing polyadenylation sites

  • Mutate SRSF7 binding motifs

  • Measure 3'UTR length changes upon SRSF7 manipulation

• Coordinate regulation with SRSF3: Investigate how SRSF7 cooperates with SRSF3:

  • Double knockdown experiments

  • Compare binding patterns between the two proteins

  • Identify transcripts regulated by both factors

• Functional consequences: Assess how SRSF7-mediated APA affects:

  • mRNA stability

  • Translation efficiency

  • miRNA targeting

  • mRNA localization

Research revealed that SRSF7, together with SRSF3, modulates 3'UTR length through suppression or enhancement of alternative polyadenylation .